BMCA-targeting agents in relapsed/refractory multiple myeloma: Distilling the data from the ASCO Annual Meeting 2020
Find out about the latest data on the use of B-cell maturation antigen (BCMA)-targeted therapies in the management of relapsed/refractory multiple myeloma through our touchCONGRESS Webinar and Expert Interviews with European experts discussing data from ASCO20 Virtual.
CME and Education Activities are developed by touchIME for touchONCOLOGY.
Our education resources are developed in collaboration with our well established peer-reviewed medical journals, our Editorial Board members and partnerships with major medical societies, with a clear commitment to high-quality independent education.